Jochen-wiesner.de

Publikationsverzeichnis PD Dr. rer. nat. Jochen Wiesner

Originalarbeiten

Gökçen A, Vilcinskas A, Wiesner J. Methods to identify enzymes that degrade the main
extracellular polysaccharide component of Staphylococcus epidermidis biofilms. Virulence.
2013 Apr 1;4(3):260-70.
Röhrich CR, Ngwa CJ, Wiesner J, Schmidtberg H, Degenkolb T, Kollewe C, Fischer R,
Pradel G, Vilcinskas A. Harmonine, a defence compound from the harlequin ladybird, inhibits
mycobacterial growth and demonstrates multi-stage antimalarial activity. Biol Lett. 2012 Apr
23;8(2):308-11.
Baumeister S, Wiesner J, Reichenberg A, Hintz M, Bietz S, Harb OS, Roos DS, Kordes M,
Friesen J, Matuschewski K, Lingelbach K, Jomaa H, Seeber F. Fosmidomycin uptake into
Plasmodium and babesia-infected erythrocytes is facilitated by parasite-induced new
permeability pathways. PLoS One. 2011 May 4;6(5):e19334.
Englert NE, Richter C, Wiesner J, Hintz M, Jomaa H, Schwalbe H. NMR studies of DOXP
reductoisomerase and its inhibitor complex. Chembiochem. 2011 Feb 11;12(3):468-76.
Rekittke I, Nonaka T, Wiesner J, Demmer U, Warkentin E, Jomaa H, Ermler U. Structure of
the E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate synthase (GcpE) from Thermus
thermophilus. FEBS Lett. 2011 Feb 4;585(3):447-51.
Xu W, Lees NS, Adedeji D, Wiesner J, Jomaa H, Hoffman BM, Duin EC. Paramagnetic
intermediates of (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE/IspG) under
steady-state and pre-steady-state conditions. J Am Chem Soc. 2010 Oct 20;132(41):14509-20.
Yan F, LaMarre JM, Röhrich R, Wiesner J, Jomaa H, Mankin AS, Fujimori DG. RlmN and
Cfr are radical SAM enzymes involved in methylation of ribosomal RNA. J Am Chem Soc.
2010 Mar 24;132(11):3953-64.
Rekittke I, Wiesner J, Röhrich R, Demmer U, Warkentin E, Xu W, Troschke K, Hintz M, No
JH, Duin EC, Oldfield E, Jomaa H, Ermler U. Structure of (E)-4-hydroxy-3-methyl-but-2-
enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. J Am Chem
Soc. 2008 Dec 24;130(51):17206-7.
Begley M, Bron PA, Heuston S, Casey PG, Englert N, Wiesner J, Jomaa H, Gahan CG, Hill
C. Analysis of the isoprenoid biosynthesis pathways in Listeria monocytogenes reveals a role
for the alternative 2-C-methyl-D-erythritol 4-phosphate pathway in murine infection. Infect
Immun. 2008 Nov;76(11):5392-401.
Kohring K, Wiesner J, Altenkämper M, Sakowski J, Silber K, Hillebrecht A, Haebel P,
Dahse HM, Ortmann R, Jomaa H, Klebe G, Schlitzer M. Development of Benzophenone-
Based Farnesyltransferase Inhibitors as Novel Antimalarials. ChemMedChem. 2008
Aug;3(8):1217-31.
Perruchon J, Ortmann R, Altenkämper M, Silber K, Wiesner J, Jomaa H, Klebe G, Schlitzer
M. Studies Addressing the Importance of Charge in the Binding of Fosmidomycin-Like
Molecules to Deoxyxylulosephosphate Reductoisomerase. ChemMedChem. 2008
Aug;3(8):1232-41.
Giessmann D, Heidler P, Haemers T, Van Calenbergh S, Reichenberg A, Jomaa H,
Weidemeyer C, Sanderbrand S, Wiesner J, Link A. Towards new antimalarial drugs:
synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-
deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors. Chem Biodivers. 2008
Apr;5(4):643-56.
Haemers T, Wiesner J, Giessmann D, Verbrugghen T, Hillaert U, Ortmann R, Jomaa H, Link
A, Schlitzer M, Van Calenbergh S. Synthesis of beta- and gamma-oxa isosteres of
fosmidomycin and FR900098 as antimalarial candidates. Bioorg Med Chem. 2008 Mar
15;16(6):3361-71.
Van Hoof S, Lacey CJ, Röhrich RC, Wiesner J, Jomaa H, Van Calenbergh S. Synthesis of
analogues of (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate, an isoprenoid precursor and
human gamma delta T cell activator. J Org Chem. 2008 Feb 15;73(4):1365-70
Wiesner J, Ortmann R, Jomaa H, Schlitzer M. Double ester prodrugs of FR900098 display
enhanced in-vitro antimalarial activity. Arch Pharm (Weinheim). 2007 Dec;340(12):667-9.
Fokin AA, Yurchenko AG, Rodionov VN, Gunchenko PA, Yurchenko RI, Reichenberg A,
Wiesner J, Hintz M, Jomaa H, Schreiner PR. Synthesis of the antimalarial drug FR900098
utilizing the nitroso-ene reaction. Org Lett. 2007 Oct 11;9(21):4379-82.
Ortmann R, Wiesner J, Silber K, Klebe G, Jomaa H, Schlitzer M. Novel
deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with
spacious acyl residues. Arch Pharm (Weinheim). 2007 Sep;340(9):483-90.
Devreux V, Wiesner J, Jomaa H, Van der Eycken J, Van Calenbergh S. Synthesis and
evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR
inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4920-3.
Burkhardt D, Wiesner J, Stoesser N, Ramharter M, Uhlemann AC, Issifou S, Jomaa H,
Krishna S, Kremsner PG, Borrmann S. Delayed parasite elimination in human infections
treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int J
Parasitol. 2007 Jun;37(7):777-85.
Devreux V, Wiesner J, Jomaa H, Rozenski J, Van der Eycken J, Van Calenbergh S.
Divergent strategy for the synthesis of alpha-aryl-substituted fosmidomycin analogues. J Org
Chem. 2007 May 11;72(10):3783-9.
Goncharenko AV, Ershov IuV, Salina EG, Wiesner J, Vostroknutova GN, Sandanov AA,
Kapel'iants AS, Ostrovskiĭ DN. [The role of 2-C-methylerythritol-2,4-cyclopyrophosphate in
the resuscitation of the "nonculturable" forms of Mycobacterium smegmatis] Mikrobiologiia.
2007 Mar-Apr;76(2):172-8.
Gorlitzer K, Enge C, Jones PG, Jomaa H, Wiesner J. [Benzo[c][2,7]naphthyridine-5-yl-
arylamines-phenol Mannich bases of the amodiaquine-, cycloquine- and pyronaridine-type]
Pharmazie. 2007 Feb;62(2):89-93.
Gorlitzer K, Bode M, Jones PG, Jomaa H, Wiesner J. [Benzo[c][2,7]naphthyridine-5-yl-
amines and benzo[h][1,6]naphthyridine-5-yl-amines--potential antimalarials] Pharmazie. 2007
Jan;62(1):15-26.
Adedeji D, Hernandez H, Wiesner J, Kohler U, Jomaa H, Duin EC. Possible direct
involvement of the active-site [4Fe-4S] cluster of the GcpE enzyme from Thermus
thermophilus in the conversion of MEcPP. FEBS Lett. 2007 Jan 23;581(2):279-83
Gorlitzer K, Enge CH, Jones PG, Jomaa H, Wiesner J. [Benzo[c][2,7]naphthyridine-2-yl-, 5-
yl- and 2,5-diyl novaldiamines--synthesis and investigation of anti-malarial activity]
Pharmazie. 2006 Dec;61(12):975-80.
Gorlitzer K, Gabriel B, Jomaa H, Wiesner J. [Thieno[3,4-c]quinoline-4-yl-amines--synthesis
and investigation of activity against malaria] Pharmazie. 2006 Nov;61(11):901-7.
Borrmann S, Lundgren I, Oyakhirome S, Impouma B, Matsiegui PB, Adegnika AA, Issifou S,
Kun JF, Hutchinson D, Wiesner J, Jomaa H, Kremsner PG. Fosmidomycin plus clindamycin
for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria.
Antimicrob Agents Chemother. 2006 Aug;50(8):2713-8.
Gorlitzer K, Gabriel B, Jomaa H, Wiesner J. [Thieno[3,2-c]quinoline-4-yl-amines--synthesis
and investigation of activity against malaria] Pharmazie. 2006 Apr;61(4):278-84.
Devreux V, Wiesner J, Goeman JL, Van der Eycken J, Jomaa H, Van Calenbergh S.
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent
Plasmodium falciparum growth inhibitors. J Med Chem. 2006 Apr 20;49(8):2656-60.
Haemers T, Wiesner J, Van Poecke S, Goeman J, Henschker D, Beck E, Jomaa H, Van
Calenbergh S. Synthesis of alpha-substituted fosmidomycin analogues as highly potent
Plasmodium falciparum growth inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1888-
91.
Kettler K, Wiesner J, Ortmann R, Dahse HM, Jomaa H, Schlitzer M. Antimalarial activity of
methylpiperazinyl-substituted benzophenone-based farnesyltransferase inhibitors. Pharmazie.
2006 Jan;61(1):63-5.
Röhrich RC, Englert N, Troschke K, Reichenberg A, Hintz M, Seeber F, Balconi E, Aliverti
A, Zanetti G, Kohler U, Pfeiffer M, Beck E, Jomaa H, Wiesner J. Reconstitution of an
apicoplast-localised electron transfer pathway involved in the isoprenoid biosynthesis of
Plasmodium falciparum. FEBS Lett. 2005 Nov 21;579(28):6433-8.
Kettler K, Wiesner J, Fucik K, Sakowski J, Ortmann R, Dahse HM, Jomaa H, Schlitzer M. 2-
(aminoacylamino)benzophenones: farnesyltransferase inhibition and antimalarial activity.
Pharmazie. 2005 Sep;60(9):677-82.
Borrmann S, Adegnika AA, Moussavou F, Oyakhirome S, Esser G, Matsiegui PB, Ramharter
M, Lundgren I, Kombila M, Issifou S, Hutchinson D, Wiesner J, Jomaa H, Kremsner PG.
Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated
Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2005 Sep;49(9):3749-54.
Ortmann R, Wiesner J, Reichenberg A, Henschker D, Beck E, Jomaa H, Schlitzer M.
Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial
activity. Arch Pharm (Weinheim). 2005 Jul;338(7):305-14.
Trutko SM, Dorofeeva LV, Evtushenko LI, Ostrovskii DN, Hintz M, Wiesner J, Jomaa H,
Baskunov BP, Akimenko VK. Isoprenoid pigments in representatives of the family
Microbacteriaceae. Mikrobiologiia. 2005 May-Jun;74(3):335-41.
Kettler K, Sakowski J, Wiesner J, Ortmann R, Jomaa H, Schlitzer M. Novel lead structures
for antimalarial farnesyltransferase inhibitors. Pharmazie. 2005 May;60(5):323-7.
Trutko SM, Dorofeeva LV, Shcherbakova VA, Chuvil'skaia NA, Laurinavichus KS, Biniukov
VI, Ostrovskiĭ DN, Hintz M, Wiesner J, Jomaa H, Akimenko VK. [Prevalence of
nonmevalonate and mevalonate pathways for isoprenoid biosynthesis among bacteria of
different systematic groups] Mikrobiologiia. 2005 Mar-Apr;74(2):185-90.
Kettler K, Wiesner J, Silber K, Haebel P, Ortmann R, Sattler I, Dahse HM, Jomaa H, Klebe
G, Schlitzer M. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-
benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial
activity. Eur J Med Chem. 2005 Jan;40(1):93-101.
Cassera MB, Gozzo FC, D'Alexandri FL, Merino EF, Del Portillo HA, Peres VJ, Almeida IC,
Eberlin MN, Wunderlich G, Wiesner J, Jomaa H, Kimura EA, Katzin AM. The
methylerythritol phosphate pathway is functionally active in all intraerythocytic stages of
plasmodium falciparum. J Biol Chem. 2004 Dec 10;279(50):51749-59.
Fucik K, Kettler K, Wiesner J, Ortmann R, Unterreitmeier D, Krauss J, Bracher F, Jomaa H,
Schlitzer M. 2-(Arylpropionylamino)- and 2-(arylacryloylamino)benzophenones:
farnesyltransferase inhibition and antimalarial activity. Pharmazie. 2004 Oct;59(10):744-52.
Yajima S, Hara K, Sanders JM, Yin F, Ohsawa K, Wiesner J, Jomaa H, Oldfield E.
Crystallographic Structures of Two Bisphosphonate:1-Deoxyxylulose-5-Phosphate
Reductoisomerase Complexes. J Am Chem Soc. 2004 Sep 8;126(35):10824-10825.
Görlitzer K, Meyer H, Jomaa H, Wiesner J. [Chloroquine analogues from benzofuro- and
benzothieno[3,2-b]-4-pyridone-2-carboxylic acid esters] Pharmazie. 2004 Aug;59(8):590-2.
Bronner S, Renault C, Hintz M, Wiesner J, Jomaa H, Monteil H, Jehl F. Determination of
fosmidomycin in human serum and urine by capillary electrophoresis. J Chromatogr B Analyt
Technol Biomed Life Sci. 2004 Jul 5;806(2):255-61.
Görlitzer K, Meyer H, Walter RD, Jomaa H, Wiesner J. Benzothieno[3,2-b]pyridin-4-yl-
amine – Synthese und Prüfung auf Wirksamkeit gegen Malaria. Pharmazie 2004
Jul;59(7):506-12.
Görlitzer K, Gabriel B, Frohberg P, Wobst I, Drutkowski G, Wiesner J, Jomaa H.
Thieno[2,3-c]chinoline – Synthese und biologische Prüfung. Pharmazie 2004 Jun;59(6):439-
42.
Görlitzer K, Meyer H, Jomaa H, Wiesner J. Benzofuro[3,2-b]pyridin-4-yl-amine – Synthese
und Prüfung auf Wirksamkeit gegen Malaria. Pharmazie 2004 Jun;59(6):443-5.

Görlitzer K, Kramer C, Meyer H, Walter RD, Jomaa H, Wiesner J. Pyrido[3,2-b]indol-4-yl-
amine – Synthese und Prüfung auf Wirksamkeit gegen Malaria“. Pharmazie 2004
Apr;59(4):243-50.
Beha E, Jung A, Wiesner J, Rimpler H, Lanzer M, Heinrich M. Antimalarial activity of
extracts of Abutilon grandiflorum G. Don - a traditional Tanzanian medicinal plant. Phytother
Res. 2004 Mar;18(3):236-40.
Borrmann S, Adegnika AA, Matsiegui PB, Issifou S, Schindler A, Mawili-Mboumba DP,
Baranek T, Wiesner J, Jomaa H, Kremsner PG. Fosmidomycin-clindamycin for Plasmodium
falciparum infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8.
Herforth C, Wiesner J, Heidler P, Sanderbrand S, Van Calenbergh S, Jomaa H, Link A.
Antimalarial activity of N(6)-substituted adenosine derivatives. Part 3. Bioorg Med Chem.
2004 Feb 15;12(4):755-62.
Wiesner J, Kettler K, Sakowski J, Ortmann R, Katzin AM, Kimura EA, Silber K, Klebe G,
Jomaa H, Schlitzer M. Farnesyltransferase inhibitors inhibit the growth of malaria parasites
in vitro and in vivo. Angew Chem Int Ed Engl. 2004 Jan;43(2):251-4.
Wiesner J, Mitsch A, Altenkamper M, Ortmann R, Jomaa H, Schlitzer M. Structure-activity
relationships of novel anti-malarial agents part 8. Effect of different central aryls in
biarylacryloylaminobenzophenones on antimalarial activity. Pharmazie. 2003
Dec;58(12):854-6.
Ortmann R, Wiesner J, Henschker D, Beck E, Jomaa H, Schlitzer M. Acyloxyalkyl ester
prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg Med Chem Lett.
2003 Jul 7;13(13):2163-6.
Wiesner J, Mitsch A, Jomaa H, Schlitzer M. Structure-activity relationships of novel anti-
malarial agents. Part 7: N-(3-Benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic
acid amides with polar moieties. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2159-61.
Wiesner J, Fucik K, Kettler K, Sakowski J, Ortmann R, Jomaa H, Schlitzer M. Structure-
activity relationships of novel anti-malarial agents. Part 6: N-(4-Arylpropionylamino-3-
benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem Lett. 2003
May 5;13(9):1539-41.
Wiesner J, Ortmann R, Mitsch A, Wissner P, Sattler I, Jomaa H, Schlitzer M. Inhibitors of
farnesyltransferase: 5-arylacryloylaminobenzophenones show antimalarial activity.
Pharmazie. 2003 Apr;58(4):289-90.
Wiesner J, Kettler K, Sakowski J, Ortmann R, Jomaa H, Schlitzer M. Structure-activity
relationships of novel anti-malarial agents: Part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-
nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem Lett. 2003 Feb;13(3):361-3.
Lell B, Ruangweerayut R, Wiesner J, Missinou MA, Schindler A, Baranek T, Hintz M,
Hutchinson D, Jomaa H, Kremsner PG. Fosmidomycin, a novel chemotherapeutic agent for
malaria. Antimicrob Agents Chemother. 2003 Feb;47(2):735-8.
Potapov VD, Bakhteeva IV, Borzenkov VN, Titareva GM, Wiesner J, Biniukov VI,
Ostrovskiĭ DN, Biketov SF. [Effect of fosfidomycin on development of various infections in
mice] Antibiot Khimioter. 2003;48(2):9-12.
Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui PB, Binder R,
Lell B, Wiesner J, Baranek T, Jomaa H, G Kremsner P. Fosmidomycin for malaria. Lancet.
2002 Dec 14;360(9349):1941-2.
Kollas AK, Duin EC, Eberl M, Altincicek B, Hintz M, Reichenberg A, Henschker D, Henne
A, Steinbrecher I, Ostrovsky DN, Hedderich R, Beck E, Jomaa H, Wiesner J. Functional
characterization of GcpE, an essential enzyme of the non-mevalonate pathway of isoprenoid
biosynthesis. FEBS Lett. 2002 Dec 18;532(3):432-6.
Altincicek B, Duin EC, Reichenberg A, Hedderich R, Kollas AK, Hintz M, Wagner S,
Wiesner J, Beck E, Jomaa H. LytB protein catalyzes the terminal step of the 2-C-methyl-D-
erythritol-4-phosphate pathway of isoprenoid biosynthesis. FEBS Lett. 2002 Dec
18;532(3):437-40.
Wiesner J, Mitsch A, Wissner P, Kramer O, Jomaa H, Schlitzer M. Structure-activity
relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-
3-(5-aryl-2-furyl)acrylic acid amides. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2681-2683.
Wiesner J, Henschker D, Hutchinson DB, Beck E, Jomaa H. In vitro and in vivo synergy of
fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob Agents Chemother.
2002 Sep;46(9):2889-94.
Herforth C, Wiesner J, Franke S, Golisade A, Jomaa H, Link A. Antimalarial activity of
N(6)-substituted adenosine derivatives (Part 2). J Comb Chem. 2002 Jul 8;4(4):302-314.
Eberl M, Altincicek B, Kollas AK, Sanderbrand S, Bahr U, Reichenberg A, Beck E, Foster D,
Wiesner J, Hintz M, Jomaa H. Accumulation of a potent gdT cell stimulator after deletion
of the lytB gene in Escherichia coli. Immunology. 2002 Jun;106(2):200-11.
Golisade A, Wiesner J, Herforth C, Jomaa H, Link A. Anti-malarial activity of N(6)-
substituted adenosine derivatives. Part I. Bioorg Med Chem. 2002 Mar;10(3):769-77.
Wiesner J, Kettler K, Jomaa H, Schlitzer M. Structure-activity relationships of novel anti-
malarial agents. Part 3: N-(4-Acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
Bioorg Med Chem Lett. 2002 Feb 25;12(4):543-545.
Reuter K, Sanderbrand S, Jomaa H, Wiesner J, Steinbrecher I, Beck E, Hintz M, Klebe G,
Stubbs MT. Crystal structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase, a crucial
enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. J Biol Chem. 2002 Feb
15;277(7):5378-5384.
Hintz M, Reichenberg A, Altincicek B, Bahr U, Gschwind RM, Kollas AK, Beck E, Wiesner
J, Eberl M, Jomaa H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as
a major activator for human gd T cells in Escherichia coli. FEBS Lett. 2001 Dec 7;509:317-
22.
Wiesner J, Mitsch A, Wissner P, Jomaa H, Schlitzer M. Structure-activity relationships of
novel anti-malarial agents: 1. arylacyl and cyclohexylacyl derivatives of 5-amino-2-
tolylacetylaminobenzophenone. Pharmazie 2001 Jun;56(6):443-444.
Altincicek B, Kollas A, Eberl M, Wiesner J, Sanderbrand S, Hintz M, Beck E, Jomaa H.
LytB, a novel gene of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid
biosynthesis in Escherichia coli. FEBS Lett. 2001 Jun 15;499(1-2):37-40.
Altincicek B., Kollas AK, Sanderbrand S, Wiesner J, Hintz M, Beck E, Jomaa H. GcpE is
involved in the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway of isoprenoid
biosynthesis. J Bacteriol. 2001 Apr 15; 183(8):2411-2416.
Wiesner J, Wissner P, Dahse HM, Jomaa H, Schlitzer M. Discovery of a novel lead structure
for anti-malarials. Bioorg Med Chem. 2001 Mar;9(3):785-792.
Reichenberg A, Wiesner J, Weidemeyer C, Dreiseidler E, Sanderbrand S, Altincicek B, Beck
E, Schlitzer M, Jomaa H. Diaryl ester prodrugs of FR900098 with improved in vivo
antimalarial activity. Bioorg. Med. Chem. Lett. 2001 Mar 26;11(6):833-835.
Wiesner J, Mitsch A, Wissner P, Jomaa H, Schlitzer M. Structure-activity relationships of
novel anti-malarial agents. Part 2: cinnamic acid derivatives. Bioorg. Med. Chem. Lett. 2001
Feb 12;11(3):423-424.
Wiesner J, Sanderbrand S, Altincicek B, Beck E, Jomaa H. Seeking new targets for
antiparasitic agents. Trends Parasitol. 2001 Jan; 17(1):7-8.
Wiesner J, Hintz M, Altincicek B, Sanderbrand S, Weidemeyer C, Beck E, Jomaa H.
Plasmodium falciparum: Detection of the deoxyxylulose 5-phosphate reductoisomerase
activity. Exp Parasitol. 2000 Nov; 96(3):182-186.
Altincicek B, Hintz M, Sanderbrand S, Sanderbrand S, Wiesner J, Beck E, Jomaa H. Tools
for discovery of inhibitors of the 1-deoxy-D-xylulose 5-phosphate (DXP) synthase and DXP
reductoisomerase: an approach with enzymes from the pathogenic bacterium Pseudomonas
aeruginosa. FEMS Microbiol Lett. 2000 Sep; 190(2):329-333.
Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Turbachova I,
Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E. Inhibitors of the nonmevalonate
pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999 Sep
3;285(5433):1573-1576.
Zeidler J, Schwender J, Müller C, Wiesner J, Weidemeyer C, Beck E, Jomaa H,
Lichtenthaler HK. Inhibition of the non-mevalonate 1-deoxy-D-xylulose-5-phosphate
pathway of plant isoprenoid biosynthesis by fosmidomycin Z Naturforsch C 1998 Nov-Dec;
53(11-12):980-986.
Wiesner J, Mattei D, Scherf A, Lanzer M. Biology of giant proteins of Plasmodium:
resolution on polyacrylamide-agarose composite gels. Parasitol Today. 1998 Jan;14(1):38-40.
Wunsch S, Sanchez CP, Gekle M, Grosse-Wortmann L, Wiesner J, Lanzer M. Differential
stimulation of the Na+/H+ exchanger determines chloroquine uptake in Plasmodium
falciparum. J Cell Biol. 1998 Jan 26;140(2):335-45.

Wiesner J, Jomaa H, Wilhelm M, Tony HP, Kremsner PG, Horrocks P, Lanzer M. Host cell
factor CD59 restricts complement lysis of Plasmodium falciparum-infected erythrocytes. Eur
J Immunol. 1997 Oct; 27(10):2708-2713.
Fischer K, Horrocks P, Preuss M, Wiesner J, Wunsch S, Camargo AA, Lanzer M. Expression
of var genes located within polymorphic subtelomeric domains of Plasmodium falciparum
chromosomes. Mol Cell Biol. 1997 Jul;17(7):3679-86.
Wiesner J. Kulturversuche mit Schleimpilzen. Mikrokosmos 1994, 83:73-80.
Wiesner J. Das Experiment: Beobachtungen an Schleimpilzen. Biologie in unserer Zeit 1992,
22:226-9.
Übersichtsartikel

Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune
system. Virulence. 2010 Sep-Oct;1(5):440-64.
Wiesner J, Reichenberg A, Heinrich S, Schlitzer M, Jomaa H. The plastid-like organelle of
apicomplexan parasites as drug target. Curr Pharm Des. 2008;14(9):855-71.
Wiesner J, Jomaa H. Isoprenoid biosynthesis of the apicoplast as drug target. Curr Drug
Targets. 2007 Jan;8(1):3-13.
Wiesner J, Seeber F. The plastid-derived organelle of protozoan human parasites as a target
of established and emerging drugs. Expert Opin Ther Targets. 2005 Feb;9(1):23-44.
Wiesner J, Ortmann R, Jomaa H, Schlitzer M. New antimalarial drugs. Angew Chem Int Ed
Engl. 2003 Nov 10;42(43):5274-93.
Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H. Microbial isoprenoid
biosynthesis and human gd T cell activation. FEBS Lett. 2003 Jun 5;544(1-3):4-10.
Wiesner J, Borrmann S, Jomaa H. Fosmidomycin for the treatment of malaria. Parasitol Res.
2003 Jun;90 Suppl 2:S71-6.
Wiesner J, Jomaa H. Fosmidomycin as novel antimalarial drug. Bioforum Europe. 2003 Feb;
7(1):40-1
Wiesner J, Borrmann S, Jomaa H. Fosmidomycin – ein neues Mittel gegen Malaria. Flug-
und Reisemedizin 2003. 10 (1):21-23

Buchbeiträge

Wiesner J, Reichenberg A, Hintz M, Ortmann R, Schlitzer M, Van Calenbergh S, Borrmann
S, Lell B, Kremsner PG, Hutchinson D, Jomaa H. Fosmidomycin as an antimalarial agent. In:
New concepts in plant and microbial isoprenoid research (ed. Bach TJ, Gershenzon J, Rohmer
M) New York: Springer, 2013, p. 119-137
Wiesner J, Vilcinskas A. Therapeutic potential of antimicrobial insect peptides. In: Insect
biotechnology (ed. Vilcinskas A) Dordrecht, The Netherlands: Springer, 2010, p. 29-65
Wiesner J. Myxomyceten – Wenn die Monster munter werden. In: Wenn Monster munter
werden: einfache Experimente aus der Biologie (Hrsg.: Keil M, Kremer BP) Weinheim:
Wiley-VCH, 2003, Seite 1-9
Patente
US2011112054 (A1) ― 2011-05-12
JOMAA HASSAN [DE]; EBERL MATTHIAS [DE]; ALTINCICEK BORAN [DE]; HINTZ
MARTIN [DE]; WOLF OLIVER [DE]; KOLLAS ANN-KRISTIN [DE]; REICHENBERG
ARMIN [DE]; WIESNER JOCHEN [DE]
Organophosphorous Compounds for the Activation of Gamma/Delta T Cells
US2008312190 (A1) ― 2008-12-18
VAN CALENBERGH SERGE [BE]; HAEMERS TIMOTHY [BE]; DEVREUX VINCENT
[BE]; JOMAA HASSAN [DE]; WIESNER JOCHEN [DE]
Organophosphoric Derivatives Useful as Anti-Parasitic Agents
WO2004035810 (A2) ― 2004-04-29
ALTINCICEK BORAN [DE]; HINTZ MARTIN [DE]; JOMAA HASSAN [DE]; KOLLAS
ANN-KRISTIN [DE]; SANDERBRAND SILKE [DE]; WIESNER JOCHEN [DE]
Method for determining enzymatic activity of proteins
US2004235784 (A1) ― 2004-11-25
JOMAA HASSAN [DE]; WIESNER JOCHEN [DE]
Combination preparations of 3-N-formylhydroxylaminopropyl phosphonic acid derivatives or
3-N-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific
pharmaceutical active agents
WO2004019956 (A1) ― 2004-03-11
ALTINCICEK BORAN [DE]; EBERL MATTHIAS [DE]; HOERAUF ACHIM [DE];
JOMAA HASSAN [DE]; WIESNER JOCHEN [DE]
Organophosphorous compounds for the treatment of helminthic infections
US2003036532 (A1) ― 2003-02-20
JOMAA HASSAN [DE]; SCHLITZER MARTIN [DE]; WIESNER JOCHEN [DE]
Use of 2-phenylene diamine derivatives for the treatment of infections
DE10134705 (A1) ― 2003-02-06 ALTINCICEK BORAN [DE]; EBERL MATTHIAS [DE]; HINTZ MARTIN [DE]; JOMAA HASSAN [DE]; KOLLAS ANN-KRISTIN [DE]; REICHENBERG ARMIN [DE]; WIESNER JOCHEN [DE]; WOLF OLIVER [DE] New acyclic or cyclic organophosphorus compounds, are gamma-delta-T cell activators useful e.g. as medicaments for treating asthma, chronic bronchitis, ulcerative colitis, autoimmune diseases or allergies WO0208235 (A1) ― 2002-01-31 JOMAA HASSAN [DE]; SCHLITZER MARTIN [DE]; WIESNER JOCHEN [DE]; DREISIEDLER ERHARD [DE] Medicament for oral application, containing aminopropyl phosphonic acid esters as an active ingredient HK1018589 (A1) ― 2006-08-18 LANG HANS JOCHEN; LANZER MICHAEL; WIESNER JOCHEN; SANCHEZ CECILIA; WUENSCH STEFAN Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa

Source: http://www.jochen-wiesner.de/Publikationsverzeichnis%20Jochen%20Wiesner.pdf